Amylyx Pharmaceuticals (AMLX) Free Cash Flow (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Free Cash Flow of -$36.9 million for Q1 2026, up 7.41% year-over-year from -$34.3 million in Q1 2025, and down 31.77% quarter-over-quarter from -$28.0 million in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Free Cash Flow (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Free Cash Flow history runs 6 years deep, the most recent figure standing at -$36.9 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 7.41% year-over-year to -$36.9 million; the TTM figure through Mar 2026 stood at -$120.5 million (up 41.8% YoY), while the FY2025 annual figure was -$123.5 million, up 26.41% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$36.9 million, down from -$28.0 million in the prior quarter.
- The five-year high for Free Cash Flow was $13.2 million in Q4 2023, with the low at -$66.7 million in Q2 2024.
- The 5-year median for Free Cash Flow is -$36.9 million (2026), against an average of -$29.4 million.
- The sharpest annual moves came in 2023 and 2025: Free Cash Flow surged 126.22% in 2023, then sank 7064.57% in 2025.
- Amylyx Pharmaceuticals' Free Cash Flow stood at -$50.3 million in 2022, then soared by 126.22% to $13.2 million in 2023, then plunged by 547.35% to -$59.0 million in 2024, then soared by 52.58% to -$28.0 million in 2025, then slumped by 31.77% to -$36.9 million in 2026.
- Business Quant data shows AMLX's Free Cash Flow at -$36.9 million in Q1 2026, -$28.0 million in Q4 2025, and -$30.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | 307.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 538.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 1.14 Bn |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 205.60 Mn |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | 329.00 Mn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 128.60 Mn |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 244.00 Mn |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | - |
| 10 | Amylyx Pharmaceuticals | 4.36 Bn | 4.36 Bn | - | -31.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -31.42 Mn |
| Jun 30, 2026 | -31.42 Mn |
| Mar 31, 2026 | -36.88 Mn |
| Mar 31, 2026 | -36.88 Mn |
| Dec 31, 2025 | -27.99 Mn |
| Dec 31, 2025 | -27.99 Mn |
| Sep 30, 2025 | -30.39 Mn |
| Sep 30, 2025 | -30.39 Mn |
| Jun 30, 2025 | -25.27 Mn |
| Jun 30, 2025 | -25.27 Mn |
| Mar 31, 2025 | -39.84 Mn |
| Mar 31, 2025 | -39.84 Mn |
| Dec 31, 2024 | -59.03 Mn |
| Dec 31, 2024 | -59.03 Mn |
| Sep 30, 2024 | -41.55 Mn |
| Sep 30, 2024 | -41.55 Mn |
| Jun 30, 2024 | -66.67 Mn |
| Jun 30, 2024 | -66.67 Mn |
| Mar 31, 2024 | -556,000.00 |
| Mar 31, 2024 | -556,000.00 |